What does a DHEA level at the low end of the normal reference range indicate, and is treatment required?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

DHEA at Low End of Normal: Clinical Significance and Management

A DHEA level at the low end of the normal reference range does NOT require treatment in most individuals, as this is a physiological finding, particularly in older adults. However, the clinical context is critical—specifically whether the patient has primary adrenal insufficiency (PAI) and associated symptoms.

Key Diagnostic Considerations

When Low-Normal DHEA Suggests Pathology

DHEAS levels well below the lower limit of normal for age and sex are a useful initial sign of PAI that should not be overlooked, although they cannot be used in isolation to make the diagnosis 1. The critical distinction is:

  • Low-normal DHEA (within reference range but at lower end): Generally physiological, especially with aging
  • DHEA below the lower limit of normal: Warrants evaluation for adrenal insufficiency

Age-Related Decline is Normal

Serum DHEAS concentrations physiologically peak between ages 20-30 years, followed by a gradual decline independent of menopause 1. This natural "adrenopause" means that low-normal values in older individuals are expected and not pathological 2.

When Treatment Should Be Considered

Specific Clinical Scenario for DHEA Replacement

DHEA replacement should only be considered in women with confirmed PAI who have specific symptoms despite optimized glucocorticoid and mineralocorticoid replacement 1. The Endocrine Society Clinical Practice Guideline (2016) provides clear criteria:

Indications for Trial of DHEA:

  • Women with PAI (not just low DHEA alone)
  • Persistent symptoms including:
    • Low libido
    • Depressive symptoms
    • Low energy levels
  • Despite otherwise optimized glucocorticoid and mineralocorticoid replacement 1

Treatment Protocol:

  • Dosing: 25-50 mg oral DHEA as single morning dose 1
  • Trial period: 6 months initially 1
  • Monitoring: Morning serum DHEAS levels (before daily dose), aiming at mid-normal range 1
  • Discontinuation: If no sustained beneficial effect after 6 months, DHEA should be stopped 1

Evidence Quality and Limitations

Mixed Evidence Base

The evidence for DHEA supplementation is notably weak. A systematic review and meta-analysis of randomized placebo-controlled trials showed no substantial clinical benefit, suggesting current evidence is insufficient to support routine use of DHEA in women with adrenal insufficiency 1. Some individual studies showed improvements in quality of life and mood, but results are inconsistent 1.

Important Caveats:

  • Studies on long-term outcomes are lacking and unlikely to be available due to lack of commercial interest 1
  • The recommendation strength is weak (Grade 2, very low-quality evidence) 1
  • DHEA replacement is NOT indicated for individuals without confirmed adrenal insufficiency, even if DHEA is low-normal

Clinical Algorithm

Step 1: Assess for Adrenal Insufficiency

If DHEA is low-normal, determine if there are other signs of PAI:

  • Low morning cortisol (<140 nmol/L or 5 μg/dL)
  • Elevated ACTH (>2-fold above upper limit)
  • Abnormal corticotropin stimulation test 1

Step 2: If PAI is Confirmed

  • Optimize glucocorticoid and mineralocorticoid replacement first
  • Assess for specific symptoms (libido, mood, energy)

Step 3: Consider DHEA Trial Only If:

  • Female patient with PAI
  • Persistent symptoms despite optimized replacement
  • Shared decision-making regarding limited evidence

Step 4: If No PAI

  • No treatment indicated—low-normal DHEA is physiological
  • Reassure patient this is age-appropriate

Common Pitfalls to Avoid

  1. Do not treat low-normal DHEA in isolation: DHEA levels alone do not diagnose adrenal insufficiency and should not trigger treatment 1

  2. Do not use DHEA as a diagnostic test alone: While very low DHEAS can suggest PAI, normal or low-normal levels do not exclude it, and confirmation requires cortisol/ACTH testing 1

  3. Avoid routine supplementation in healthy individuals: Despite recreational use trends, there is insufficient evidence for DHEA supplementation in people without adrenal insufficiency 3

  4. Do not continue ineffective treatment: If no benefit after 6 months, discontinue rather than continuing indefinitely 1

References

Related Questions

What does a low dehydroepiandrosterone sulfate (DHEAS) level indicate in a 39‑year‑old male?
How should I evaluate and manage a patient with low dehydroepiandrosterone (DHEA) levels?
What does a DHEA‑S level of 37 µg/dL indicate and what management steps are recommended?
In a 47‑year‑old woman with a DHEA‑sulfate level of 199 ng/dL and a morning cortisol level of 7.6 µg/dL, what is the clinical significance and what evaluation and management steps are recommended?
What is the significance of a DHEA‑S (dehydroepiandrosterone sulfate) level of 199 ng/dL and how should it be evaluated and managed?
What is the recommended protocol for transitioning a patient from methotrexate to adalimumab (Humira)?
Can Vraylar (cariprazine) cause tremor?
Is methylphenidate appropriate for performance enhancement in individuals without a diagnosed attention‑deficit/hyperactivity disorder (ADHD)?
What is the recommended starting dose of alprazolam for an adult with generalized anxiety disorder, and how should the dosing be adjusted for panic disorder, elderly patients, those with hepatic impairment, or benzodiazepine‑naïve individuals?
What is the recommended further oncology management for a 79‑year‑old female with a history of ER/PR‑positive, HER2‑negative stage II breast cancer who declined chemotherapy, completed radiation and aromatase inhibitor therapy, and now presents with a loculated right pleural effusion, pleural thickening, bilateral pulmonary nodules, mediastinal lymphadenopathy, and a destructive sternal mass suggestive of metastatic disease?
What is the appropriate next step in management for an inconclusive thyroid fine‑needle aspiration biopsy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.